Artiva Biotherapeutics, Inc. (ARTV) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $726.59M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-21.00K; Retained Earnings (Accumulated Deficit)USD $-379.07M.
- 2026-03-31: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $441.93M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-18.00K; Retained Earnings (Accumulated Deficit)USD $-354.06M.
- 2025-12-31: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $440.41M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $103.00K; Retained Earnings (Accumulated Deficit)USD $-330.55M.
- 2025-09-30: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $438.91M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $87.00K; Retained Earnings (Accumulated Deficit)USD $-309.78M.
Artiva Biotherapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00K | $726.59M | $-21.00K | $-379.07M | $347.50M | 3 month · $1.86M |
| 2026-03-31 | $3.00K | $441.93M | $-18.00K | $-354.06M | $87.85M | 3 month · $1.59M |
| 2025-12-31 | $3.00K | $440.41M | $103.00K | $-330.55M | $109.97M | 12 month · $6.82M |
| 2025-09-30 | $3.00K | $438.91M | $87.00K | $-309.78M | $129.22M | 3 month · $1.63M |
| 2025-06-30 | $3.00K | $437.29M | $2.00K | $-288.25M | $149.04M | 3 month · $1.55M |
| 2025-03-31 | $3.00K | $435.77M | (m) | $-267.00M | $168.78M | 3 month · $2.05M |
| 2024-12-31 | $3.00K | $433.45M | $-129.00K | $-246.68M | $186.64M | 12 month · $6.98M |
| 2024-09-30 | $3.00K | $431.24M | $338.00K | $-230.59M | $201.00M | 3 month · $1.91M |
| 2024-06-30 | (m) | $21.90M | $121.00K | $-213.12M | $-191.10M | 3 month · $1.48M |
| 2024-03-31 | (m) | (m) | (m) | (m) | $-174.67M | 3 month · $1.41M |
| 2023-12-31 | (m) | $18.99M | $308.00K | $-181.31M | $-162.01M | 12 month · $7.05M |
| 2023-09-30 | (m) | (m) | (m) | (m) | $-151.45M | 3 month · $1.37M |
| 2023-06-30 | (m) | (m) | (m) | (m) | $-164.25M | 3 month · $2.46M |
| 2023-03-31 | (m) | (m) | (m) | (m) | $-155.57M | 3 month · $1.83M |
| 2022-12-31 | (m) | (m) | (m) | (m) | $-140.70M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |